Здоровье без побочных эффектов

33. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283: 373–80.

34. Ziegler M.G., Lew P., Singer B.C. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273: 1296–8.

35. Steinman M.A., Harper G.M., Chren M.M., et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007; 4: e134.

36. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004; 351: 1885–90.

37. Chren M.M., Landefeld C.S. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684–9.

38. Orlowski J.P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992; 102: 270–3.

39. Morgan S.G., Bassett K.L., Wright J.M., et al. ‘Breakthrough’ drugs and growth in expenditure on prescription drugs in Canada. BMJ. 2005; 331: 815–6.

40. Johansen H.K., Gøtzsche P.C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.

41. Jørgensen K.J., Johansen H.K., Gøtzsche P.C. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006; 7: 3.

42. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981–97.

43. Lieberman J.A., Stroup T.S., McEvoy, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209–23.

44. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63: 1079–87.

45. Woo W.W.K., Man S.-Y., Lam P.K.W., et al. Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinfl ammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med. 2005; 46: 352–61.

46. Villanueva P., Peiró S., Librero J., et al. Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003; 361: 27–32.

47. Wilkes M.S., Doblin B.H., Shapiro M.F. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.

48. Jørgensen A.W., Hilden J., Gøtzsche P.C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006; 333: 782–5.

49. Malhotra D. Pharmaceutical lies. BMJ. 2006 Oct 28.

50. Spurling G.K., Mansfield P.R., Montgomery B.D., et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010; 7: e1000352.

51. Bowman M.A., Pearle D.L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.

52. Bowman M.A. The impact of drug company funding on the content of continuing medical education. Möbius. 1986; 6: 66–9.

53. Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).

54. Tramèr M.R., Reynolds D.J., Moore R.A., et al. Impact of covert duplicate publication on metaanalysis: a case study. BMJ. 1997; 315: 635–40.

55. Aspinall R.L., Goodman N.W. Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ. 1995; 311: 844–6.

56. Carlisle J., Stevenson C.A. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006; 3: CD004125.